The top 20 biopharma companies averaged a market capitalisation decline of $3.45 trillion in Q2 to $3.14 trillion in Q3 2022, says GlobalData.
List view / Grid view
Children with cystic fibrosis aged six to11 years could benefit from Kaftrio® in combination with ivacaftor, as a treatment targeting the underlying cause of the disease.
The first Pharmaceutical Invention Index, which looks at the breadth and depth of novel agents currently being developed within the most innovative pharma pipelines, has been released.
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
1 July 2016 | By Caroline Richards, Editor, European Pharmaceutical Review
Here, Caroline Richards, Editor of European Pharmaceutical Review, discusses cystic fibrosis and the treatment options that are currently available or in development...
20 November 2015 | By Victoria White
Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis...
18 May 2015 | By Victoria White
Data from two Phase 3 studies of Orkambi, an investigational medicine designed to treat the underlying cause of cystic fibrosis, have been published...
24 April 2015 | By Victoria White
The combined spend on research and development (R&D) for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, says leading research and consulting firm GlobalData.